Biocon Biologics in Saudi Arabia
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing.
It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
Expanding Access to Lifesaving Therapies in AFMET
In the Africa-Midde East, Turkey (AFMET) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, diabetes, and autoimmune conditions through its commercialized biosimilars.
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia. The integrated insulins manufacturing and R&D facility in Malaysia, the largest in Asia, manufactures a broad portfolio of regular, basal, and rapid-acting insulins.
Focused on Making a Meaningful Difference in Saudi Arabia
Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in Saudi Arabia. Biocon Biologics has seven commercialized products in Saudi Arabia — Ogivri (Trastuzumab), Krabeva (Bevacizumab), Fulphila (Pegfilgrastim), Neucyte (Pegfilgrastim), Semglee (Insulin Glargine), Hulio (Adalimumab) and Nepexto (Etanercept).
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Saudi Arabia. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Saudi Arabia, making a meaningful impact on patients’ lives. In Saudi Arabia, Hulio and Nepexto are commercialized by our partner Boston Oncology, Semglee is commercialized by our partner Al Rajhi Pharma, Krabeva and Neucyte are distributed by our partner Jamjoom Medical Co., and Ogivri and Fulphila are distributed by our partner Cigalah.
Commercialized Products
| Sl. No | Brand Name | Molecule Name | THERAPY AREA |
| 1 | Ogivri^ | Trastuzumab | Cancer |
| 2 | Krabeva# | Bevacizumab | Cancer |
| 3 | Fulphila^ | Pegfilgrastim | Cancer |
| 4 | Neucyte# | Pegfilgrastim | Cancer |
| 5 | Semglee** | Insulin Glargine | Diabetes |
| 6 | Hulio* | Adalimumab | Immunology |
| 7 | Nepexto* | Etanercept | Immunology |
* Hulio and Nepexto are commercialized by our partner Boston Oncology in Saudi Arabia
** Semglee is commercialized by our partner Al Rajhi Pharma in Saudi Arabia
# Krabeva and Neucyte are distributed by our partner Jamjoom Medical Co. in Saudi Arabia
^ Ogivri and Fulphila are distributed by our partner Cigalah in Saudi Arabia
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates